Talvy | $2,000,000 | (Mar 11, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Sigma360 | $17,000,000 | (Mar 11, 2026)
Korsana Biosciences
United States
- Waltham, MA
- 19/02/2026
- Unknown
- $175,000,000
Korsana Biosciences is a private biopharmaceutical company advancing a pipeline of potential best-in-class therapies for neurodegenerative diseases. In partnership with Paragon Therapeutics, we have developed Therapeutic Targeting (THETA™), a novel blood-brain barrier-penetrant shuttle platform designed to enable dramatically higher drug concentration inside the brain and overcome the limitations of earlier shuttle technologies. Our lead program is KRSA-028, an investigational, shuttled antibody targeting amyloid beta designed to be a best-in-class treatment for Alzheimer’s disease. Our mission is to advance precision-engineered therapies, designed to address some of the biggest unmet needs in medicine. For more information, please visit www.korsana.com
- Industry Biotechnology Research
- Website https://korsana.com/
- LinkedIn https://www.linkedin.com/company/korsana-biosciences/
Related People
Jonathan ViolinFounder
United States -
Seasoned CEO, board member, and accomplished scientist passionate about leading drug discovery and development, building effective scientific platforms, and forging relationships that drive company creation, growth, and financing. Raised over $1B in capital for public and private biotech companies. Recognized for strategic leadership, integrity, clear communication of scientific and clinical concepts, and fostering transparency and credibility with internal and external stakeholders.
R2 Wireless | $5,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)
Lux Aeterna | $10,000,000 | (Mar 11, 2026)
Amigo | $11,000,000 | (Mar 11, 2026)
Axiom Trust Company | $11,800,000 | (Mar 11, 2026)
Sandbar | $23,000,000 | (Mar 11, 2026)
Jazz | $61,000,000 | (Mar 11, 2026)
PactFi | $25,000,000 | (Mar 11, 2026)
Advocacy | $3,500,000 | (Mar 10, 2026)